Oncolytics Biotech Inc. (TSX:ONC)
Canada · Delayed Price · Currency is CAD | Market Cap | 142.51M |
| Revenue (ttm) | n/a |
| Net Income | -30.41M |
| EPS | -0.37 |
| Shares Out | 100.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 109,627 |
| Open | 1.420 |
| Previous Close | 1.390 |
| Day's Range | 1.390 - 1.440 |
| 52-Week Range | 0.445 - 2.080 |
| Beta | 1.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 1, 2025 |
About Oncolytics Biotech
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing... [Read more]
Financial Performance
Financial StatementsNews
Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep's Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growth
Penny Stock Oncolytics Biotech Says Colorecatal Cancer Drug's Durability Tops Historical Benchmarks
Oncolytics Biotech, Inc. (NASDAQ:ONCY) shares are up on Monday as the company reported promising durability data for its investigational immunotherapy, pelareorep, in treating metastatic colorectal ca...
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-M...
Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer Study
Company to leverage strong durability and survival data in second-line and later metastatic squamous cell anal carcinoma Pivotal study expected to focus on patients in a post-standard-of-care patient ...
Oncolytics Schedules Type C Meeting With FDA For Pelareorep In Anal Cancer
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Monday announced that it has scheduled a Type C meeting with the U.S. Food and Drug Administration FDA on April 1...
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational,...
Oncolytics Biotech® Completes Domicile Change to the United States
SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the...
Oncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026
Pelareorep treatment drives coordinated immune activation and tertiary lymphoid structure formation Translational data suggest potential to boost response to immunotherapy and targeted therapy in RAS...
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC , March 5, 2026 /CNW/ -- Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70...
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC , March 3, 2026 /CNW/ --The global oncology market is projected to nearly triple from $279.98 billion in 2026...
Oncolytics Biotech® Launches Randomized Colorectal Cancer Study
Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L KRA...
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Focus on Key Trials
Oncolytics Biotech (ONCY) Ends Enrollment in GOBLET Study to Focus on Key Trials
Oncolytics Biotech® to Prioritize Registration-Focused Programs in Anal and Colorectal Cancer
Company to wind down the GOBLET gastrointestinal study to focus on registration path in the U.S. With sufficient cash on hand to execute near-term milestones, the Company expects to avoid immediate ma...
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Treatment
Oncolytics Biotech (ONCY) Secures FDA Fast Track for Cancer Treatment
Oncolytics Biotech® Receives FDA Fast Track Designation for Pelareorep in 2L KRAS-Mutant MSS Metastatic Colorectal Cancer
Strong efficacy signals showing 33% ORR, 16.6-month PFS, and 27-month OS, improving on the SOC by 2-3X in a difficult-to-treat population
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
SAN DIEGO, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the ...
Oncolytics Biotech Names John McAdory EVP Of Strategy & Operations; Yujun Wu To Head Biostatistics
(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company , announced the appointment of John McAdory as Executive Vice President of Strategy and Operations and Yujun Wu as Vi...
The $185B Cancer Surge: Why the FDA’s Fast-Track Pivot is Scaling a New Immunotherapy Era
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) — USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from it...
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer
Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with no appr...
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided addit...
Oncolytics Biotech® Provides Update on Intellectual Property Strategy and Patent Filings
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the statu...
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O'Reilly, Dr. Neil Segal, and Dr. Van Morris
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the expansion of its ...
Oncolytics Biotech® Announces Promising Efficacy and Translational Data Supporting Pelareorep in KRAS-Mutant Metastatic Colorectal Cancer
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced clinical and translat...
Oncolytics Biotech® Reschedules Special Meeting of Shareholders to Change Jurisdiction of Incorporation to Nevada
SAN DIEGO--(BUSINESS WIRE)--Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced it has filed an amend...
Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Oncolytics Biotech (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ...